Harrow Health (HROW)
NASDAQ:HROW
Want to see HROW full AI Analyst Report?
HROW Stock Chart & Stats
$41.50
-$0.36(-1.00%)
At close: 4:00 PM EST
$41.50
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$28.54 - $54.85
Previous CloseN/A
Volume51.77K
Average Volume (3M)1.00M
Market Cap
$1.60B
Enterprise Value$1.77B
Total Cash (Recent Filing)$94.64M
Total Debt (Recent Filing)$300.67M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Aug 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding37,275,110
10 Day Avg. Volume847,604
30 Day Avg. Volume1,004,126
Financial Highlights & Ratios
PEG Ratio4.90
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio42.12
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue6.59
Enterprise Value/Gross Profit8.89
Enterprise Value/Ebitda56.23
Forecast
1Y Price Target
$68.20Price Target Upside64.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.3
Revenue Forecast (FY)$348.37M
Bulls Say, Bears Say
Bulls Say
Strong Commercial Demand And Market-share Gains (VEVYE, TRIESENCE, IHEEZO)Sustained prescription growth, expanding prescriber base and accelerating TRIESENCE volumes indicate durable end-market adoption. Consistent unit and account gains suggest structural demand, supporting multi-quarter revenue scalability and stronger commercial leverage as the salesforce converts higher prescriptions into recurring sales.
High Gross Margins And Improving Operating Cash GenerationElevated gross margins preserve core product economics and provide room to invest in commercial expansion. Coupled with a turnaround to positive operating/free cash flow in recent periods, this quality of margins supports sustainable reinvestment in sales and pipeline development while helping absorb temporary revenue fluctuations.
Commercial Scale-up And Multiple Structural Product CatalystsA materially enlarged field force and staged product catalysts (J‑code, distributor stocking, new launches and G‑MELT development) create durable upside pathways. These investments increase distribution depth, accelerate prescriber coverage and position the company to monetize next‑wave launches over multiple quarters and years.
Bears Say
Elevated Leverage And Weakened Equity CushionSubstantially higher leverage materially increases financial fragility; interest and principal obligations limit strategic optionality and increase refinancing risk. A thin equity base constrains the firm's ability to fund growth internally and raises the probability of costly debt or dilutive equity if revenue or cash generation falters.
Persistent Net Losses And Uneven ProfitabilityOngoing GAAP losses and periodic negative adjusted EBITDA reduce internal capital for R&D and commercialization and limit shock absorption. Even with operating improvements, persistent bottom-line deficits constrain free-cash-flow sustainability under stress and raise execution pressure on management to achieve profitable scale.
Revenue Volatility From Payer/gross-to-net Dynamics And Channel TimingReimbursement mix shifts, buydowns and reporting lags create structural unpredictability in realized pricing and revenue recognition. Combined with channel inventory timing and unquantified near-term contributions from new launches, these dynamics can persistently mute top-line predictability and complicate margin and cash forecasting across multiple quarters.
Harrow Health News
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $28.54 and its highest was $54.85 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $1.60B.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is Aug 11, 2026 which is in 51 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on May 11, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.399 by -$0.341.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is -0.17.
How many shares outstanding does Harrow Health have?
Harrow Health has 37,275,110 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.399. Following the earnings report the stock price went down -23.686%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.20 (64.34% Upside)
$68.20 (64.34% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 682.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $468.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.00%
12-Months-Change
Fundamentals
Return on Equity
-33.65%
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
HROW Company Deck
HROW Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized consistently strong and accelerating demand across Harrow's core commercial products (VEVYE, IHEEZO, TRIESENCE), successful commercial investments (significant salesforce expansion), operational recoveries (Access+), multiple upcoming catalysts (multiunit packaging, clinical data, BYOOVIZ/BYQLOVI launches, IOPIDINE J-code) and reaffirmed full-year guidance. The principal near-term negative was a discrete $8M VEVYE gross-to-net revenue reduction driven by an unexpected high-deductible patient mix and reporting lags, plus a negative adjusted EBITDA in Q1 and some channel inventory timing for IHEEZO. Management identified and implemented corrective actions and expects sequential improvement beginning in Q2 and stronger performance in H2 2026. Overall, positives around demand, market share gains, commercial scale and pipeline progress substantially outweigh the discrete operational and timing headwinds.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$68.20
▲(64.34% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
20.11% Insiders
9.78% Mutual Funds
24.26% Other Institutional Investors
34.42% Public Companies and Individual Investors